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The copy number of the HBA1 assay for the -(α)^20.5^ deletion in the HBA-CNV method described in the original article \[[@CR1]\] was incorrectly reported. The authors wish to note that the HBA1 assay will not be affected by the --(α)^20.5^ deletion and will show two copies (Table [1](#Tab1){ref-type="table"} - corrected). The 3′ breakpoint of the --(α)^20.5^ deletion is located within exon 2 of the HBA1 gene \[[@CR2]\], leaving intact the area where the HBA1 assay is amplifying. The partial deletion of HBA1 causes a complete abolition of the gene expression, hence --(α)^20.5^ is considered as a double gene deletion. This shows that even though the HBA1 assay may show two copies, a deletion affecting both alpha-globin genes can not be excluded. Similarly, the Hb Var database contains examples of deletions that will not influence HBA2 assay copy number despite affecting both alpha-globin genes. Hence, molecular data should always be evaluated together with hematological data. Table 1Predicted copy number in 108 patient samplesGenotypeSamples (n)Copy Number PredictedHBA1HBA3.7HBA2HS-40αα/αα632222 -α^3.7^/αα222122 -α^4.2^/αα22212 -α^3.7^/-α^3.7^82022 \--^SEA^/αα71112 \--^FIL^/αα11112 -(α)^20.5^/αα12112 \--^MED^/αα11112 -α^3.7^/\--^SEA^11012αα/ααα^anti3.7^22322Total108
